What happened with BHST today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
BioHarvest Sciences Inc.’s main business is VINIA, a powder made from red-grape cells grown in its bioreactors rather than from harvested grapes. It sells the powder in capsules and incorporates it into foods and drinks. These consumer products generate nearly all revenue, with the United States and Israel as principal markets. Most sales come through VINIA.com and VINIA.co.il, with a smaller share through Amazon Marketplace. Customer subscriptions provide recurring sales, making renewals important to continued revenue.
The company also earns fees from developing plant-based active molecules for pharmaceutical and other health-product companies. This smaller business uses the same plant-cell technology under service agreements. Its pharmaceutical contract remains in development; commercial-scale manufacturing depends on successful completion of later stages.
Production depends on the Yavne No. 1 facility in Israel, where the company expects products supporting all near-term revenue to be made. It also uses a third-party manufacturer to turn its VINIA powder into several finished foods and drinks. U.S. food sales rely on the company’s own determination that VINIA is generally recognized as safe, which the FDA has not reviewed. Food and supplement rules also restrict labeling and health claims and can prevent sales if requirements are not met.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
BioHarvest’s results hinge mainly on winning and retaining VINIA supplement customers and scaling production profitably, while services that develop and manufacture products for other companies still contribute little revenue.
Lifevantage Corporation competes with BioHarvest for health-conscious consumers buying supplements and hydration products marketed around science, but relies more on independent consultants to sell them than BioHarvest’s e-commerce approach. Repeat purchases of Lifevantage’s supplements and AXIO drink mixes are worth watching as a sign of demand in the consumer market VINIA also targets.
Lifevantage Corporation earningsLFVN
Lifevantage Corporation's report will show whether health-conscious consumers keep buying its supplements and drink mixes, a customer market BioHarvest also targets with VINIA.
Watch whether demand for LifeVantage's supplements and AXIO drink mixes supports repeat purchases. Resilient demand would suggest the health-conscious consumer market both companies target remains supportive of VINIA; weaker demand would point to a cooler market. LifeVantage relies more on independent consultants, while BioHarvest sells mainly through its own websites and Amazon, so this is a market signal, not a direct measure of BioHarvest sales.
BioHarvest Sciences Inc. earningsThis company
BioHarvest Sciences earns most of its revenue from VINIA and other products, and this report will show whether product sales can grow while the Products gross margin holds up.
Read Products revenue alongside the Products gross margin. Revenue growth with a steady or higher margin would mean BioHarvest is selling more without weakening the economics of its main business; weaker revenue or a falling margin could point to softer demand or higher manufacturing and selling costs. The test is whether growth makes the product business sturdier.
